1 |
<p><b>The Partnership</b></p> |
2 |
<p>Many years of research led PLIVA to the development of a valuable drug with |
3 |
huge therapeutic and marketing potential. In 1981, PLIVA filed a patent application |
4 |
for azithromycin in the former Yugoslavia, which was followed by further applications |
5 |
worldwide, including in the United States. PLIVA's first patent for azithromycin |
6 |
was granted in Belgium. In 1988 PLIVA registered azithromycin under the brand |
7 |
name Sumamed.</p> |
8 |
<p>PLIVA chose Pfizer as its strategic and licensing partner because of Pfizer's |
9 |
overall capabilities and track record and because its international presence |
10 |
and sales force complemented PLIVA's presence in Central and Eastern Europe. |
11 |
Additionally, Pfizer had developed additional understanding of azithromycin |
12 |
as a result of its own research in this area. For PLIVA, the licensing agreement |
13 |
meant a huge breakthrough in terms of annual revenues and the expansion of research |
14 |
activities.</p> |
15 |
<p><b>The Medicine</b></p> |
16 |
<p>Azithromycin acts by interfering with bacterial protein synthesis. Although |
17 |
this mechanism is considered bacteriostatic, concentrations several times higher |
18 |
than minimum inhibitory concentrations (MIC) contribute to the bactericidal |
19 |
activity of azithromycin.</p> |
20 |
<p>Azithromycin is rapidly absorbed and distributed throughout body tissues, reaching |
21 |
high and sustained tissue concentrations that result in sustained antimicrobial |
22 |
activity. Since azithromycin is a weak base, it easily penetrates the cell membrane |
23 |
and stays within the cell, mainly in lysosomes. High concentrations of azithromycin |
24 |
are found in infected tissues since phagocytes, polymorphonuclear leukocytes |
25 |
and macrophages deliver azithromycin to the infection site and release it there |
26 |
in the presence of bacteria.</p> |
27 |
<p>Those pharmacokinetic properties of azithromycin in combination with wide antimicrobial |
28 |
activity give the drug wide therapeutic applications. For the majority of infections, |
29 |
azithromycin is administered once daily for three days. In the treatment of |
30 |
sexually transmitted diseases, azithromycin is administered as a single dose |
31 |
and in the treatment of <i>erythema migrans</i> once daily over 5 days. Azithromycin's |
32 |
short dosing regimen is convenient for the patients and improves patient compliance.</p> |
33 |
<p>In clinical trials, azithromycin showed itself to be either better or equally |
34 |
well tolerated, compared to other antibiotics. The tolerability and safety profile |
35 |
of azithromycin (Sumamed) have been assessed in 4,727 patients enrolled in clinical |
36 |
trials carried out in Croatia, the Czech Republic, Hungary, Macedonia, Poland, |
37 |
the Slovak Republic, Slovenia, Russia and the former Yugoslavia. In addition, |
38 |
azithromycin, unlike the majority of macrolides, does not bind to cytochrome |
39 |
P-450 in the liver, resulting in low potential for drug to drug interaction.</p> |